Zai Lab (ZLAB) Preferred Stock Liabilities (2016)

Zai Lab's (ZLAB) quarterly Preferred Stock Liabilities came in at $134.5 million in Q4 2016.

Zai Lab (ZLAB) Preferred Stock Liabilities (2016) Analysis & Trends

Zai Lab has disclosed Preferred Stock Liabilities across 1 years of filings, most recently posting $134.5 million for Q4 2016.

Preferred Stock Liabilities for Q4 2016 came in at $134.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was $134.5 million (changed N/A YoY), and the FY2016 annual result was $134.5 million, changed N/A from the prior year.
Preferred Stock Liabilities came in at $134.5 million for Q4 2016 at Zai Lab.
In the past five years, Preferred Stock Liabilities ranged from a high of $134.5 million in Q4 2016 to a low of $134.5 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Zai Lab	20.15 Bn	20.05 Bn	61.30 Mn	-

Download Data

Date	Value
Dec 31, 2016	134.51 Mn